<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:arxiv="http://arxiv.org/schemas/atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>q-bio.GN updates on arXiv.org</title>
    <link>http://rss.arxiv.org/rss/q-bio.GN</link>
    <description>q-bio.GN updates on the arXiv.org e-print archive.</description>
    <atom:link href="http://rss.arxiv.org/rss/q-bio.GN" rel="self" type="application/rss+xml"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <language>en-us</language>
    <lastBuildDate>Tue, 19 Aug 2025 11:27:50 +0000</lastBuildDate>
    <managingEditor>rss-help@arxiv.org</managingEditor>
    <pubDate>Tue, 19 Aug 2025 00:00:00 -0400</pubDate>
    <skipDays>
      <day>Saturday</day>
      <day>Sunday</day>
    </skipDays>
    <item>
      <title>Mechanism of Quercetin in Inhibiting Triple-Negative Breast Cancer by Regulating T Cell-Related Targets: An Analysis Based on Single-Cell Sequencing and Network Pharmacology</title>
      <link>https://arxiv.org/abs/2508.12731</link>
      <description>arXiv:2508.12731v1 Announce Type: cross 
Abstract: Objective: To investigate the mechanism by which quercetin inhibits triple-negative breast cancer (TNBC) through regulating T-cell-related targets, providing a novel strategy for TNBC immunotherapy.Methods: Single-cell RNA sequencing (GSE161529 dataset) and network pharmacology were integrated. PCA and UMAP clustering identified T-cell subsets and differentially expressed genes in TNBC microenvironment. TNBC-related targets were screened via CTD and OMIM databases, with functional pathways analyzed by GO/KEGG enrichment. Molecular docking and PPI networks validated interactions between quercetin and core targets.Results: Quercetin intersected with 79 TNBC targets, including AKT1, EGFR, and MMP9, enriched in EGFR inhibitor resistance and endocrine resistance pathways. Molecular docking revealed the highest affinity between quercetin and GSK3B (-13.2 kJ/mol). AKT1 and MMP9 expression correlated with patient survival.Conclusion: Quercetin may reverse TNBC immunosuppression by multi-target modulation of T-cell function, but clinical application requires solutions for its low bioavailability, such as delivery systems or combination therapies.</description>
      <guid isPermaLink="false">oai:arXiv.org:2508.12731v1</guid>
      <category>q-bio.MN</category>
      <category>q-bio.GN</category>
      <pubDate>Tue, 19 Aug 2025 00:00:00 -0400</pubDate>
      <arxiv:announce_type>cross</arxiv:announce_type>
      <dc:rights>http://arxiv.org/licenses/nonexclusive-distrib/1.0/</dc:rights>
      <dc:creator>Ruiqi Chen, Liang Hang, Fengyun Wang</dc:creator>
    </item>
  </channel>
</rss>
